ISSN 1006-298X      CN 32-1425/R

导航

肾脏病与透析肾移植杂志 ›› 2011, Vol. 20 ›› Issue (2): 173-175.

• 论文 • 上一篇    下一篇

活性维生素D与营养性维生素D在慢性肾脏病治疗中的临床地位

  

  • 出版日期:2011-04-28 发布日期:2011-06-02

Active versus Nutritional Vitamin D Compounds in Clinical Outcomes of Chronic Kidney Disease

  • Online:2011-04-28 Published:2011-06-02

摘要:

大多数终末期肾病患者存在25(OH)D不足或缺乏。然而,选择何种维生素D制剂治疗目前还尚存争议。KDOQI指南推荐,针对25(OH)D水平降低(<30ng/ml)引发的继发性甲状旁腺功能亢进的非透析慢性肾脏病(CKD)患者,可采用营养性维生素D(NVD)作为治疗的首选药物。然而迄今为止,尚无研究表明营养性维生素D能提高CKD患者生存率,仅一些小样本研究显示可降低甲状旁腺素(PTH)水平,改善机体对促红细胞生成素敏感性及糖代谢,但上述临床试验在设计或实施上均存在着明显不足。与此相反,活性维生素D显著的生存优势则日益突出,包括可更有效地降低CKD患者死亡率和冠状动脉钙化增加的生物标记物--碱性磷酸酶水平。

关键词: 慢性肾脏病 , 活性维生素D , 营养性维生素D

Abstract:

The serum levels of 25-hydroxyvitamin D insufficiency or deficiency remains common in most individuals with end-stage renal disease (ESRD). However, it is still argued that which kind of vitamin D analogues-active vitamin D or nutritional vitamin D, is used for treatment. Kidney Disease Outcome Quality Initiative (K/DOQI) guideline suggests that nutritional vitamin D(NVD) is initiated to treat nondialysis chronic kidney disease (CKD) patients with secondary hyperparathyroidism for low levels of 25-hydroxyvitamin D (<30ng/ml).Though some small sample studies, which exist significant defects on design or implementation of clinical trials, showed that nutritional vitamin D can decrease levels of parathyroid hormone, and improve sensitivity to erythropoietin stimulating agents and glycemic, nutritional vitamin D is not proved to improve survival. In contrast, active vitamin D can exert significant survival advantage on reducing mortality of CKD patients and increased biochemical marker-alkaline phosphatase, with coronary artery calcification.

Key words: chronic kidney disease , active vitamin D , nutritional vitamin D